Table 3.
Cancer family histories in first- or second-degree relatives (excluding breast cancer) reported by the 26 patients with breast cancer and the XRCC2 c.96delT mutation compared to those reported by the 11,672 patients with breast cancer and without the XRCC2 c.96delT mutation
| Cancer site | Number (%) of cancers in relatives of XRCC2 c.96delT positive patients (n = 26 families) | Number (%) of cancers in relatives of XRCC2 c.96delT negative patients (n = 11672 families) | ||
|---|---|---|---|---|
| Bladder | 0 | 0.0% | 133 | 1.1% |
| Brain | 1 | 3.8% | 251 | 2.1% |
| Colon | 3 | 11.5% | 896 | 7.7% |
| Kidney | 0 | 0.0% | 324 | 2.8% |
| Larynx | 0 | 0.0% | 452 | 3.9% |
| Lung | 5 | 19.2% | 1728 | 14.8% |
| Melanoma | 0 | 0.0% | 96 | 0.8% |
| Leukemia or Lymphoma | 1 | 3.8% | 452 | 3.9% |
| Skin (non-melanoma) | 0 | 0.0% | 147 | 1.3% |
| Pancreas | 2 | 7.7% | 336 | 2.9% |
| Prostate | 2 | 7.7% | 783 | 6.7% |
| Stomach | 1 | 3.8% | 1000 | 8.6% |
| Ovary/uterus | 5 | 19.2% | 1782 | 15.3% |
| Any site | 20 | 76.9% | 8380 | 71.8% |
Family history in first- and second-degree relatives was available for 26 of 29 XRCC2 mutation carriers and 11,672 of 12,588 non-carriers